Madrigal Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Madrigal Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Madrigal Pharmaceuticals: 17 sponsored US clinical trials, 1 recruiting.
Madrigal Pharmaceuticals sponsors 17 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 4 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is NASH - Nonalcoholic Steatohepatitis, with 2 trials.
Top-decile sponsor footprint
Madrigal Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
17 total, page 1 of 1
Rezdiffra Pregnancy and Lactation Registry
NCT07541469
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
NCT06397872
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
NCT04197479
Drug Interaction Study of MGL-3196 With Clopidogrel
NCT04671069
Drug Interaction Study of MGL-3196 With Pioglitazone
NCT04671056
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
NCT04643795
Bioavailability Study of MGL-3196 Tablets Compared to Capsules
NCT03413124
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
NCT03220165
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
NCT02912260
Drug Interaction Study of MGL-3196 With Atorvastatin
NCT02749578
Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
NCT02542969
Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects
NCT01519531
Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects
NCT01367873
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 2 |
| Phase 3 | 4 |
What is open in the Madrigal Pharmaceuticals pipeline
1 recruiting of 17 indexed (6% open); 12 completed (71%).
Phase mix: 4 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: NASH - Nonalcoholic Steatohepatitis (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Madrigal Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 17 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Madrigal Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 trials (± recruiting share)
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Colgate Palmolive · 6% recruiting · 51 trials
- Durham VA Medical Center · 6% recruiting · 17 trials
- Essentia Health · 6% recruiting · 17 trials
- Southern Methodist University · 6% recruiting · 17 trials
Related
What to do with this Madrigal Pharmaceuticals page
17 registered trials is a research-attention snapshot, not an endorsement of Madrigal Pharmaceuticals or any single study.
- 1 of Madrigal Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- NASH - Nonalcoholic Steatohepatitis is the condition Madrigal Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See NASH - Nonalcoholic Steatohepatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Madrigal Pharmaceuticals pipeline card: 17 registered trials from official public datasets.Report a data error.